CA2494744A1 - Utilisation d'extrait de germe de ble fermente comme agent anti-inflammatoire - Google Patents
Utilisation d'extrait de germe de ble fermente comme agent anti-inflammatoire Download PDFInfo
- Publication number
- CA2494744A1 CA2494744A1 CA002494744A CA2494744A CA2494744A1 CA 2494744 A1 CA2494744 A1 CA 2494744A1 CA 002494744 A CA002494744 A CA 002494744A CA 2494744 A CA2494744 A CA 2494744A CA 2494744 A1 CA2494744 A1 CA 2494744A1
- Authority
- CA
- Canada
- Prior art keywords
- avemar
- day
- inflammatory agent
- treatment
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940121363 anti-inflammatory agent Drugs 0.000 title claims abstract description 16
- 239000002260 anti-inflammatory agent Substances 0.000 title claims abstract description 16
- 241000209140 Triticum Species 0.000 title claims abstract description 15
- 235000021307 Triticum Nutrition 0.000 title claims abstract description 15
- 239000000284 extract Substances 0.000 title claims abstract description 15
- 239000010205 Avemar Substances 0.000 claims abstract description 53
- 239000003814 drug Substances 0.000 claims abstract description 16
- 206010003246 arthritis Diseases 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 14
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 7
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical group OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 208000009386 Experimental Arthritis Diseases 0.000 description 32
- 230000000694 effects Effects 0.000 description 28
- 241000700159 Rattus Species 0.000 description 24
- 210000002683 foot Anatomy 0.000 description 21
- 239000004480 active ingredient Substances 0.000 description 18
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 11
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 230000037396 body weight Effects 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 229960003957 dexamethasone Drugs 0.000 description 10
- 230000002757 inflammatory effect Effects 0.000 description 10
- 229960000905 indomethacin Drugs 0.000 description 9
- 230000008595 infiltration Effects 0.000 description 9
- 238000001764 infiltration Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 150000003431 steroids Chemical class 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 6
- 108010036949 Cyclosporine Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000003435 antirheumatic agent Substances 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 229960001265 ciclosporin Drugs 0.000 description 4
- 229930182912 cyclosporin Natural products 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 210000001258 synovial membrane Anatomy 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 231100000460 acute oral toxicity Toxicity 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960003677 chloroquine Drugs 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 239000000701 coagulant Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 231100000086 high toxicity Toxicity 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000010972 statistical evaluation Methods 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- -1 thinners Substances 0.000 description 2
- 229960001017 tolmetin Drugs 0.000 description 2
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017865 Gastritis erosive Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 229940127448 Interleukin-6 Antagonists Drugs 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 208000037039 Monarthritis Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- BVAYTJBBDODANA-UHFFFAOYSA-N Prednisolon Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 BVAYTJBBDODANA-UHFFFAOYSA-N 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 208000025255 bacterial arthritis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 1
- 210000002745 epiphysis Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000002134 immunopathologic effect Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 229940063121 neoral Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Chemical class 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne une nouvelle utilisation thérapeutique d'un extrait de germe de blé fermenté sous le nom commercial de Avemar®, et en particulier l'utilisation d'Avemar® pour fabriquer un médicament utile comme agent anti-inflammatoire pour prévenir, traiter ou atténuer des affections inflammatoires, notamment l'arthrite.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0202638A HUP0202638A3 (en) | 2002-08-09 | 2002-08-09 | Use of fermented wheat-germ extract for preparation of antiphlogistic compositions |
| HUP0202638 | 2002-08-09 | ||
| PCT/HU2003/000065 WO2004014406A1 (fr) | 2002-08-09 | 2003-08-08 | Utilisation d'extrait de germe de ble fermente comme agent anti-inflammatoire |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2494744A1 true CA2494744A1 (fr) | 2004-02-19 |
Family
ID=89980690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002494744A Abandoned CA2494744A1 (fr) | 2002-08-09 | 2003-08-08 | Utilisation d'extrait de germe de ble fermente comme agent anti-inflammatoire |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1536809A1 (fr) |
| JP (1) | JP2006501214A (fr) |
| KR (1) | KR20050059066A (fr) |
| CN (1) | CN1674924A (fr) |
| AU (1) | AU2003255854A1 (fr) |
| BR (1) | BR0313589A (fr) |
| CA (1) | CA2494744A1 (fr) |
| EA (1) | EA007844B1 (fr) |
| HR (1) | HRP20050114A2 (fr) |
| HU (1) | HUP0202638A3 (fr) |
| IL (1) | IL166732A0 (fr) |
| MX (1) | MXPA05001469A (fr) |
| NO (1) | NO20051168L (fr) |
| PL (1) | PL375391A1 (fr) |
| WO (1) | WO2004014406A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104381450A (zh) * | 2014-10-15 | 2015-03-04 | 张士远 | 治疗胃粘膜损伤的保健牛奶及其制备方法 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2908998A1 (fr) * | 2006-11-24 | 2008-05-30 | Bao Quoc Ho | Nouveau produit enzymatique et son utilisation. |
| HUP0900614A2 (en) | 2009-09-29 | 2011-05-30 | Mate Dr Hidvegi | Preparation comprising dehydrated, fermented material with amorphous crystaline structure and process for its production |
| WO2010135580A2 (fr) * | 2009-05-20 | 2010-11-25 | The Regents Of The University Of California | Protéines de germe de blé fermenté (fwgp) pour le traitement du cancer |
| US20120164132A1 (en) * | 2010-08-02 | 2012-06-28 | Mate Hidvegi | Anticancer and immunomodulating molecules and fractions containing said molecules, and process for preparing said fractions and said molecules from fermented vegetal material, and their uses |
| GB201108560D0 (en) | 2011-05-20 | 2011-07-06 | 3 Ch Ltd | Use of fermented wheat germ in the treatment of inflammatory bowel disease |
| GB201110746D0 (en) | 2011-06-23 | 2011-08-10 | Biropharma Uk Ltd | Wheat germ derived material |
| JP6115995B2 (ja) * | 2013-04-24 | 2017-04-19 | 株式会社日清製粉グループ本社 | 非酵素的糖化反応抑制剤 |
| WO2017196048A1 (fr) * | 2016-05-11 | 2017-11-16 | 씨제이제일제당 (주) | Composition à application externe pour soulager les rides de la peau, contenant un extrait de produit de germe de blé fermenté en tant qu'ingrédient actif |
| WO2018056600A1 (fr) * | 2016-09-23 | 2018-03-29 | 씨제이제일제당 (주) | Composition topique pour apaiser la peau, contenant comme principe actif un extrait de germe de blé fermenté |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07242537A (ja) * | 1994-03-04 | 1995-09-19 | Kibun Foods Inc | 抗炎症活性物質の製造方法および抗炎症剤 |
| JPH08337536A (ja) * | 1995-06-14 | 1996-12-24 | Asahi Breweries Ltd | 抗活性酸素作用剤並びにこれを有効成分とする抗活性酸素剤、化粧料、食品及び医薬品 |
| HU223344B1 (hu) * | 1997-08-13 | 2004-06-28 | Máté Hidvégi | Immunstimuláns és metasztázist gátló fermentált, szárított anyag, ezt tartalmazó gyógyszerkészítmények, eljárás az előállítására és alkalmazásai |
-
2002
- 2002-08-09 HU HU0202638A patent/HUP0202638A3/hu unknown
-
2003
- 2003-08-08 EP EP03784303A patent/EP1536809A1/fr not_active Withdrawn
- 2003-08-08 WO PCT/HU2003/000065 patent/WO2004014406A1/fr not_active Application Discontinuation
- 2003-08-08 EA EA200500326A patent/EA007844B1/ru not_active IP Right Cessation
- 2003-08-08 BR BR0313589-6A patent/BR0313589A/pt not_active Application Discontinuation
- 2003-08-08 MX MXPA05001469A patent/MXPA05001469A/es unknown
- 2003-08-08 PL PL03375391A patent/PL375391A1/xx not_active Application Discontinuation
- 2003-08-08 KR KR1020057002283A patent/KR20050059066A/ko not_active Application Discontinuation
- 2003-08-08 CA CA002494744A patent/CA2494744A1/fr not_active Abandoned
- 2003-08-08 JP JP2004527076A patent/JP2006501214A/ja active Pending
- 2003-08-08 CN CNA038189003A patent/CN1674924A/zh active Pending
- 2003-08-08 AU AU2003255854A patent/AU2003255854A1/en not_active Abandoned
-
2005
- 2005-02-03 HR HR20050114A patent/HRP20050114A2/hr not_active Application Discontinuation
- 2005-02-07 IL IL16673205A patent/IL166732A0/xx unknown
- 2005-03-04 NO NO20051168A patent/NO20051168L/no not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104381450A (zh) * | 2014-10-15 | 2015-03-04 | 张士远 | 治疗胃粘膜损伤的保健牛奶及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0202638A3 (en) | 2007-08-28 |
| HRP20050114A2 (en) | 2005-10-31 |
| HU0202638D0 (fr) | 2002-10-28 |
| EP1536809A1 (fr) | 2005-06-08 |
| NO20051168L (no) | 2005-03-04 |
| EA200500326A1 (ru) | 2005-06-30 |
| EA007844B1 (ru) | 2007-02-27 |
| MXPA05001469A (es) | 2005-06-06 |
| BR0313589A (pt) | 2005-07-12 |
| KR20050059066A (ko) | 2005-06-17 |
| HUP0202638A2 (hu) | 2004-06-28 |
| PL375391A1 (en) | 2005-11-28 |
| AU2003255854A1 (en) | 2004-02-25 |
| JP2006501214A (ja) | 2006-01-12 |
| IL166732A0 (en) | 2006-01-15 |
| CN1674924A (zh) | 2005-09-28 |
| WO2004014406A1 (fr) | 2004-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1964730B (zh) | 预防和治疗风湿及炎症性疾病的中药复方和相应的制备方法 | |
| HRP20050114A2 (en) | Use of fermented wheat germ extract as anti-inflammatory agent | |
| US20220133836A1 (en) | Pharmaceutical composition made from hydrophobic phytochemicals dispersed in sesame oil to enhance bioactivity | |
| CN104127758A (zh) | 具有健脾养胃功效的中药组合物及其制备方法和应用 | |
| WO2021213232A1 (fr) | Application d'une composition de médecine chinoise traditionnelle dans la préparation d'un médicament pour traiter ou prévenir l'hyperlipidémie | |
| Brendler et al. | Devil’s Claw (Harpagophytum procumbens DC) an evidence-based systematic review by the natural standard research collaboration | |
| CN100355448C (zh) | 一种防治酒精性肠道损伤和肝损伤的中药复方制剂 | |
| CN112439018A (zh) | 具有减肥降脂的组合物及其制备方法和应用 | |
| CN114470042B (zh) | 一种防治动物肝损伤的组合物及其制备方法和用途 | |
| US20050266106A1 (en) | Use of fermented wheat germ extract as anti-inflammatory agent | |
| CN100579564C (zh) | 一种治疗痛风的药物及其制备方法 | |
| DE102005005086A1 (de) | Naturheilmittel-Nahrungsergänzungs-Kombinationspräparat | |
| JP2958198B2 (ja) | 鎮痛用医薬組成物 | |
| KR100541424B1 (ko) | 항염증성 생약 조성물 및 이의 제조방법 | |
| KR100435825B1 (ko) | 변비 치료용 조성물 | |
| CN112870250B (zh) | 防治器官纤维化的组合物及其应用与制剂 | |
| CN110123871B (zh) | 一种提升白细胞及排毒作用的中药组合物制剂及制备方法 | |
| CN110215474B (zh) | 一种活血化瘀中药组合物及其应用 | |
| CN115607639B (zh) | 一种治疗银屑病的中药组合物及其制备方法 | |
| CN113842461B (zh) | 用于缓解、治疗酒精中毒、酒后不适的gabaa受体结合物、组合物及其应用 | |
| KR20040089258A (ko) | 솔잎, 녹차 및 홍차 추출물을 유효성분으로 함유하는 비만및 변비 치료용 조성물 | |
| CN1209139C (zh) | 一种主治血管性痴呆的中药及其制备方法 | |
| CN111588777A (zh) | 一种降血脂的枸杞组合物 | |
| CN118021857A (zh) | 金缕半枫荷在制备预防和/或治疗肝损伤药物中的应用 | |
| JPH1129488A (ja) | ピコスルファートナトリウムを含有する医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |